Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton 3800, Victoria, Australia.
Cabrini Monash University Department of Surgery, Cabrini Hospital, Malvern 3144, Victoria, Australia.
J Immunol. 2021 Jan 15;206(2):310-320. doi: 10.4049/jimmunol.2001203.
Over the past decade, T cell immunotherapy has changed the face of cancer treatment, providing robust treatment options for several previously intractable cancers. Unfortunately, many epithelial tumors with high mortality rates respond poorly to immunotherapy, and an understanding of the key impediments is urgently required. Cancer-associated fibroblasts (CAFs) comprise the most frequent nonneoplastic cellular component in most solid tumors. Far from an inert scaffold, CAFs significantly influence tumor neogenesis, persistence, and metastasis and are emerging as a key player in immunotherapy resistance. In this review, we discuss the physical and chemical barriers that CAFs place between effector T cells and their tumor cell targets, and the therapies poised to target them.
在过去的十年中，T 细胞免疫疗法改变了癌症治疗的格局，为几种以前难以治疗的癌症提供了强有力的治疗选择。不幸的是，许多死亡率高的上皮肿瘤对免疫疗法反应不佳，迫切需要了解关键的障碍。癌症相关成纤维细胞（CAFs）是大多数实体瘤中最常见的非肿瘤细胞成分。CAFs 远非一种惰性支架，它们显著影响肿瘤的新生、持续存在和转移，并成为免疫疗法耐药性的关键因素。在这篇综述中，我们讨论了 CAFs 在效应 T 细胞与其肿瘤细胞靶标之间设置的物理和化学障碍，以及准备针对这些障碍的治疗方法。
